Finance

Beta
Lists
LRMR:NASDAQ
Larimar Therapeutics Inc
$3.17
-3.65%
(-0.12) 1D
$3.21
+1.26% (+0.040)
After hours
Closed: Jun 5, 4:00:01 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for LRMR...
Open
$3.25
High
$3.26
Low
$3.12
Mkt. cap
329.31M
Avg. vol.
1.74M
Volume
1.24M
52-wk high
$6.42
52-wk low
$2.22
EPS
-$2.08
Beta
0.83
Shares outstanding
103.88M
No. of employees
71
Open
$3.25
High
$3.26
Low
$3.12
Mkt. cap
329.31M
Avg. vol.
1.74M
Volume
1.24M
52-wk high
$6.42
52-wk low
$2.22
EPS
-$2.08
Beta
0.83
Shares outstanding
103.88M
No. of employees
71
Analyst outlook
Analyst Ratings
Based on 5 analysts giving stock ratings to LRMR in the past 3 months
Strong Buy
Buy
5
Hold
0
Sell
0
12 month forecast
Based on 5 Wall Street analysts offering 12 month price targets for LRMR in the last 3 months.
Highest
Current $3.17
$25.00 (+688.64%)
Average
$15.00 (+373.19%)
Lowest
$9.00 (+183.91%)
News stories
From sources across the web
About Larimar Therapeutics Inc
CEO-
Employees71
Founded2005
HeadquartersBala Cynwyd, Pennsylvania, United States
SectorBiotechnology
Websitelarimartx.com
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
23.27M
44.83M
59.17M
24.93M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
4.52M
4.67M
4.84M
6.19M
Operating expense
27.79M
49.50M
64.02M
31.12M
Total operating expenses
27.79M
49.50M
64.02M
31.12M
Operating income
-27.79M
-49.50M
-64.02M
-31.12M
Other non operating income
1.61M
1.79M
1.52M
1.50M
EBT including unusual items
-26.18M
-47.71M
-62.50M
-29.61M
EBT excluding unusual items
-26.18M
-47.71M
-62.50M
-29.61M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-26.18M
-47.71M
-62.50M
-29.61M
Net profit margin
-
-
-
-
Earnings per share
-0.41
-0.61
-0.73
-0.31
Interest and investment income
-
-
-
-
Interest expense
-
-
-
-
Net interest expenses
-
-
-
-
Depreciation and amortization charges
-
-
-
-
EBITDA
-27.70M
-49.41M
-63.93M
-31.05M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer